Transfusion and Apheresis Science最新文献

{"title":"Alemtuzumab and thrombotic thrombocytopenic purpura: Analysis of an international surveillance database and systematic literature review","authors":"Jeremy W. Jacobs ,&nbsp;Thomas C. Binns ,&nbsp;Danielle Schlafer ,&nbsp;Jennifer S. Woo ,&nbsp;Garrett S. Booth ,&nbsp;Brian D. Adkins","doi":"10.1016/j.transci.2025.104081","DOIUrl":"10.1016/j.transci.2025.104081","url":null,"abstract":"<div><h3>Objectives</h3><div>Thrombotic thrombocytopenic purpura (TTP) is a thrombotic microangiopathy associated with severe deficiency in ADAMTS13. ADAMTS13 deficiency may be secondary to absent or dysfunctional protein production due to mutations in the <em>ADAMTS13</em> gene (congenital TTP) or autoantibody-mediated clearance and/or inhibition (immune-mediated TTP). This autoimmunity may, albeit rarely, occur secondary to certain medications (eg, ticlopidine). Recent case reports have implicated alemtuzumab (LETRADA), a monoclonal antibody that selectively inhibits CD52, as a cause of secondary TTP. We aimed to characterize all reports of TTP potentially associated with alemtuzumab.</div></div><div><h3>Methods</h3><div>We performed a cross-sectional analysis of the United States Food and Drug Administration’s Adverse Event Reporting System (FAERS) database as of 21 November 2024 and systematically reviewed the literature as of 03 September 2024 for all reported cases of secondary TTP potentially associated with alemtuzumab. Patient demographics, therapy indications, associated medications, and outcomes were abstracted.</div></div><div><h3>Results</h3><div>We identified 49 reports of TTP possibly related to alemtuzumab administration since 01 January 2001 in the FAERS database, 9 of which resulted in death. Most patients (n = 31) were receiving alemtuzumab for multiple sclerosis (MS), while 8 reports were in patients undergoing hematopoietic stem cell transplantation. We identified two additional cases in the literature review in patients receiving alemtuzumab for MS.</div></div><div><h3>Conclusions</h3><div>In conjunction with studies of the United Kingdom’s and European Union’s pharmacovigilance databases, these results support the current package insert for alemtuzumab in which TTP is listed as a “warning and precaution”. Increased awareness of this possible side effect, and prolonged monitoring, is warranted.</div></div>","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"64 2","pages":"Article 104081"},"PeriodicalIF":1.4,"publicationDate":"2025-01-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143069153","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Pilot evaluation of LR EXT sets of the Reveos automated blood processing system","authors":"Karan Kumar ,&nbsp;Priyadarsini Jayachandran Arcot ,&nbsp;Purushottam Kalla ,&nbsp;Sukanya Santra ,&nbsp;Mrinal Samanta","doi":"10.1016/j.transci.2025.104070","DOIUrl":"10.1016/j.transci.2025.104070","url":null,"abstract":"<div><h3>Introduction</h3><div>The Reveos automated blood processing system is the only system developed till date, which can separate whole blood into components on complete automation. Their proprietary LR and NLR blood collection sets have their own advantages and disadvantages. Using LR sets, leukodepleted components can be prepared but individual platelet units cannot be prepared. Using NLR sets, individual platelet units can be prepared, but components are non-leukodepleted. The newly launched LR EXT with the apparent advantage of both LR and NLR sets have been evaluated in this pilot study.</div></div><div><h3>Methodology</h3><div>Blood components prepared from 31 LR EXT sets were evaluated in this study in comparison with the National regulations and with components routinely prepared from LR and NLR sets.</div></div><div><h3>Results</h3><div>Excluding under-collected and sero-reactive units, components prepared from 27 LR EXT sets were evaluated for their quality. QC of PRBC units prepared had a mean volume of 296.86 ml, Hct of 59.2 % and WBC count as low as 0.06 × 106 per bag. FFP units had a mean volume of 221.89 ml, mean Fibrinogen of 432.47 mg and FVIII levels of 98.13 IU per bag. PLT units had a mean volume of 73.07 ml, PLT count of 5.74 × 1010 and WBC count of 3.21 × 108 per bag.</div></div><div><h3>Conclusion</h3><div>The use LR EXT blood collection sets help in achieving adequate inventory of both LD-PRBCs and RDPs especially in blood centres with a lower daily collection rate.</div></div>","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"64 2","pages":"Article 104070"},"PeriodicalIF":1.4,"publicationDate":"2025-01-21","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143048401","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"UV immunothrombotic trombocytopenic purpura","authors":"María Luisa Antelo Caamaño,&nbsp;Saioa Zalba Marcos,&nbsp;Maria Piva Sánchez Antón,&nbsp;José Antonio García-Erce","doi":"10.1016/j.transci.2024.104066","DOIUrl":"10.1016/j.transci.2024.104066","url":null,"abstract":"","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"64 2","pages":"Article 104066"},"PeriodicalIF":1.4,"publicationDate":"2025-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143043006","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Weak or partial D: Importance of molecular characterization of D variants","authors":"Akshaya Tomar ,&nbsp;Rati Devendra ,&nbsp;Disha Parchure ,&nbsp;Swati Kulkarni","doi":"10.1016/j.transci.2025.104069","DOIUrl":"10.1016/j.transci.2025.104069","url":null,"abstract":"<div><div>This case report presents first case of <em>RHD*weak D type 9</em> in a 38-year-old Indian patient with severe osteoarthritis of the left hip joint scheduled for total hip replacement surgery. During routine blood grouping, an unexpected weak reaction with anti-D was observed. Serological characterization using an extended partial D typing kit characterized the variant as DV. The patient was successfully transfused with a O RhD negative compatible unit as per transfusion guidelines after surgery, without any observed transfusion reactions. The blood sample was sent to the ICMR-National Institute of Immunohematology, Mumbai, where molecular characterization revealed the presence of an <em>RHD* 01 W.9</em> allele, as the underlying cause of weak expression of the RhD antigen. Serology can at best lead to the detection of the presence of a variant but characterization requires the help of molecular techniques.</div></div>","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"64 2","pages":"Article 104069"},"PeriodicalIF":1.4,"publicationDate":"2025-01-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143014953","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trends in syphilis seroreactivity among blood donors: A 17-year retrospective analysis and follow-up at a tertiary care hospital","authors":"Kshitija Mittal ,&nbsp;Paramjit Kaur ,&nbsp;Ravneet Kaur ,&nbsp;Gagandeep Kaur ,&nbsp;Arpita Parmar ,&nbsp;Shivangi Sharma","doi":"10.1016/j.transci.2025.104068","DOIUrl":"10.1016/j.transci.2025.104068","url":null,"abstract":"<div><h3>Background and objectives</h3><div>This study aimed to assess the seroprevalence of syphilis among blood donors, evaluate the response rate of seroreactive donors, and investigate high-risk behaviors.</div></div><div><h3>Material and methods</h3><div>The study presents a retrospective analysis of syphilis seroreactivity among blood donors over a 17 year period. Blood donations were screened for syphilis using the Rapid Plasma Reagin (RPR) card test. RPR-reactive blood units were discarded, and donors were notified for follow-up. A detailed history was obtained, including prior syphilis diagnoses, sexual practices, and potential high-risk activities. The donors who were repeatedly RPR reactive were referred for further confirmatory management.</div></div><div><h3>Results</h3><div>A total of 569 (0.20 %) donors were found RPR reactive. A non-linear trend was observed between RPR reactivity and study period, donor age and donation status. RPR reactivity was significantly higher in repeat blood donors (p &lt; 0.001). The mean donor return rate was significantly higher following introduction of phone calls along with letters for donor notification compared to notification via letters only (p &lt; 0.001). Forty-five percent (n = 241) donors returned for repeat sample testing. Of these, 19 % (n = 45) tested negative on repeat RPR testing while 81.3 % (n = 196) remained RPR reactive and were referred for further management. On follow up of the latter group, 43.9 % (n = 86) donors were negative on confirmatory testing indicating biological false positives while 56.1 % (n = 110) donors were positive on confirmatory testing and were true positives. Of true positive donors, 90.9 % of donors reported engaging in high risk sexual behaviours.</div></div><div><h3>Conclusion</h3><div>There is a need to update syphilis screening guidelines in developing countries like India, incorporating combination testing to improve the accuracy of syphilis detection in blood donors.</div></div>","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"64 2","pages":"Article 104068"},"PeriodicalIF":1.4,"publicationDate":"2025-01-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143014952","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Case report: Plasma exchange treatment in a patient with severe tetanus","authors":"Shijie Huang ,&nbsp;Fei Han ,&nbsp;Qishuo Zhang ,&nbsp;WeiHao Hu ,&nbsp;Kai Gao ,&nbsp;Yang Xie","doi":"10.1016/j.transci.2024.104038","DOIUrl":"10.1016/j.transci.2024.104038","url":null,"abstract":"<div><div>Tetanus, a severe illness caused by Clostridium tetani, entails symptoms such as muscle spasms and tissue necrosis due to the production of tetanus toxin and hemolysin, posing a grave risk to life. Plasma exchange is infrequently used in tetanus treatment due to limited reported cases, guidelines, the relative rarity of tetanus cases, the high cost and technical complexity of the treatment, and the need to carefully balance risks and benefits. In this case study, a 57-year-old male with a recent foot injury presented with classical tetanus symptoms, including lockjaw, neck stiffness, and lower limb hypertonicity. Upon admission, his condition deteriorated rapidly, leading to cardiac arrest. Following successful resuscitation, he was admitted to the ICU. The patient underwent plasma exchange due to persistent symptoms, ultimately showing partial functional recovery and being discharged for rehabilitation. Clinical evidence supports plasma exchange's ability to eliminate macromolecules, autoantibodies, immune complexes, cytokines, and inflammatory mediators from the body. Despite its uncommon use in tetanus infections, our patient's treatment with plasma exchange facilitated toxin removal and alleviated persistent symptoms. This case contributes to expanding our understanding and offers a novel therapeutic option for severe tetanus cases.</div></div>","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"64 1","pages":"Article 104038"},"PeriodicalIF":1.4,"publicationDate":"2024-11-25","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142744258","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Evaluating the safety and efficacy of plasma therapy/plasmapheresis for systemic sclerosis – A comprehensive systematic review","authors":"Saira Bano ,&nbsp;Inshal Jawed ,&nbsp;Muhammad umair abdul qadir ,&nbsp;Syed Ali Farhan Abbas Rizvi ,&nbsp;Vikash Kumar Karmani ,&nbsp;Farah Alam ,&nbsp;Abdul Haseeb ,&nbsp;Hina Khan ,&nbsp;Agha Muhammad Wali Mirza ,&nbsp;Naheed Akhtar ,&nbsp;Abu Huraira Bin Gulzar ,&nbsp;Khabab Abbasher Hussien Mohamed Ahmed","doi":"10.1016/j.transci.2024.104036","DOIUrl":"10.1016/j.transci.2024.104036","url":null,"abstract":"<div><h3>Introduction</h3><div>Systemic sclerosis (SSc) is an autoimmune disorder with fibrosis in multiple organs, autoantibodies, and microvascular abnormalities. Its origin is unclear, but it may result from circulatory damage, collagen metabolism disruption, and modifications in immunoregulation. The disease affects various organs and has high morbidity and mortality rates. SSc-related complications are managed using immunosuppressive medications that target autoantibodies. The main objective of this study was to assess the safety and efficacy of plasma therapy/plasmapheresis in managing SSc.</div></div><div><h3>Methods</h3><div>This systematic review followed PRISMA and IMRAD guidelines, using PICO framework for study selection based on MeSH terms and Boolean operators. It included cross-sectional, randomized control trials, and clinical studies on plasma therapy for SSc. Standardized protocols were used for data extraction and risk of bias assessment.</div></div><div><h3>Discussion</h3><div>Plasma therapy is a growing treatment option for managing SSc with reported benefits, especially in early stages and specific organ complications. However, further investigation and standardized protocols are needed. This review explores the potential of plasma therapy in improving the quality of life for SSc patients and in combination with other treatments.</div></div><div><h3>Result</h3><div>The review analyzed 15 articles, including research papers, controlled trials, and case reports. Plasma therapy, involving Plasmapheresis and therapeutic plasma exchange (TPE), improved symptoms of SSc like Raynaud phenomenon, vasculitis, muscle dysfunction, and digital ulcers. However, outcomes varied among studies, and some advanced cases showed limited benefits.</div></div><div><h3>Conclusion</h3><div>Plasma therapy can be an effective way of managing the symptoms of systemic sclerosis with low incidence of adverse events. However, the exact mechanism behind this treatment is still unclear. Therefore, additional studies are required.</div></div>","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"64 1","pages":"Article 104036"},"PeriodicalIF":1.4,"publicationDate":"2024-11-23","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142744745","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"The Italian registry of therapeutic apheresis in SISTRA: Year of activity 2023","authors":"Giustina De Silvestro ,&nbsp;Liviana Catalano ,&nbsp;Giuseppe Marano ,&nbsp;Vanessa Piccinini ,&nbsp;Simonetta Pupella ,&nbsp;Angelo Ostuni ,&nbsp;Vincenzo De Angelis","doi":"10.1016/j.transci.2024.104037","DOIUrl":"10.1016/j.transci.2024.104037","url":null,"abstract":"<div><div>The Italian Registry of Therapeutic Apheresis (IRTA) collects clinical data on patients undergoing therapeutic apheresis procedures throughout the national territory, with the main objective of improving the quality and safety of the care provided to the patient. Given the importance of centralizing the collection and analysis of information on therapeutic apheresis, the National Blood Center (NBC), at the request of the Italian Scientific Society of Hemapheresis and Cellular Manipulation (SIdEM), has included IRTA in the Information System of Transfusion Services (SISTRA), which is the information system of the Ministry of Health for the exchange of data on blood and its derivatives between the Italian Regions and the NBC. This manuscript reports IRTA activity data for 2023 maintaining the general approach introduced in previous manuscripts to facilitate comparison with already published activity data (2020–2022). For each therapeutic apheresis procedure (more than 15) we reported the number of procedures, the number of patients treated, and adverse effects. Furthermore, for each pathology belonging to more than 8 specialized clinical areas we reported the number of procedures, the number of patients treated, the number of patients at first diagnosis and the outcome of the patients. More than 36000 procedures in more than 8500 patients were included in the 2023 database. The aim of the IRTA 2023 activity data is to provide an updated snapshot of the use of therapeutic apheresis in the treatment of human diseases in Italy and a strategic resource for institutions and scientific societies.</div></div>","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"64 1","pages":"Article 104037"},"PeriodicalIF":1.4,"publicationDate":"2024-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142717369","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Comparison of different concentrations of calcium gluconate added in replacement fluid to maintain ionised calcium levels during therapeutic plasma exchange procedures","authors":"Nippun Prinja ,&nbsp;Rekha Hans ,&nbsp;Aarushi Sahni ,&nbsp;Sangeeta Kumari ,&nbsp;Preeti Paul ,&nbsp;Divjot Singh Lamba ,&nbsp;Aastha Takkar ,&nbsp;Karthik Vinay Mahesh ,&nbsp;Ratti Ram Sharma","doi":"10.1016/j.transci.2024.104039","DOIUrl":"10.1016/j.transci.2024.104039","url":null,"abstract":"<div><h3>Introduction</h3><div>Therapeutic plasma exchange (TPE) is generally well tolerated but Anticoagulant Citrate Dextrose Solution A (ACD-A) can cause citrate mediated hypocalcaemia so, adding calcium gluconate to the replacement fluid is effective in preventing this complication. We aimed to compare the effect of different concentrations of 10 % calcium gluconate (9.3 mg of elemental calcium/100 ml Vs 18.6 mg of elemental calcium/100 ml) added to 5 % Human Serum Albumin (HSA) on intraprocedural and post procedural ionised calcium (iCa2+) levels in patients with neurological conditions undergoing TPE.</div></div><div><h3>Material and methods</h3><div>This study comprised of 100 TPE procedures divided into two groups of 50 each. In group 1, 5 ml of 10 % calcium gluconate was added in 500 ml of 5 % HSA (9.3 mg of elemental calcium/100 ml) and in group 2, 10 ml of 10 % calcium gluconate was added (18.6 mg of elemental calcium/100 ml) in 5 % of HSA. Ionised calcium was noted-pre, intra and post-procedure and compared within the groups along with other procedural parameters and adverse events if any.</div></div><div><h3>Results</h3><div>We observed that mean intraprocedural ionised calcium levels were comparable (p = 0.579) in both the groups, but post-procedural iCa2+ levels significantly decreased (p = 0.003) in group-1 as compared to group-2. Symptomatic hypocalcaemia was seen in 14 % of patients group 1 compared to 2 % in group-2. Vasovagal reactions were 8 % in group-1 % and 2 % in group-2.</div></div><div><h3>Conclusion</h3><div>Prophylactic addition of 18.6 mg of elemental calcium/100 ml of 5 % HSA is safe to maintain levels of iCa2+ throughout the procedure with lower chances of adverse events related to hypocalcaemia.</div></div>","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"64 1","pages":"Article 104039"},"PeriodicalIF":1.4,"publicationDate":"2024-11-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142720216","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Mechanistic insights from a pilot exploratory study of the dynamic proteomic changes during plasma exchange in patients with acute liver failure","authors":"Benoit Jauniaux ,&nbsp;Laura Burke ,&nbsp;Nicola Snook ,&nbsp;Marina Karakantza ,&nbsp;Maria Kerr ,&nbsp;Michelle Wilson ,&nbsp;Alexandre Zougman ,&nbsp;Mark Bellamy ,&nbsp;Rosamonde E. Banks ,&nbsp;Joanna Moore","doi":"10.1016/j.transci.2024.104028","DOIUrl":"10.1016/j.transci.2024.104028","url":null,"abstract":"<div><h3>Background &amp; aims</h3><div>Therapeutic plasma exchange (PEX) has shown potential in improving transplant-free survival in acute liver failure (ALF) however the mechanism of action is not understood. This exploratory study aimed to elucidate the circulating proteomic changes associated with PEX in ALF to provide insight into mechanisms underlying the benefit of this therapy.</div></div><div><h3>Methods</h3><div>Consecutive patients admitted with ALF between June 2019 and August 2020 were enrolled. Patients received either standard medical treatment (n = 5) or PEX (n = 5). Plasma samples were collected at multiple time points and analysed using the Olink Proximity Extension Assay. Comparative analyses included healthy controls and Octaplas batches.</div></div><div><h3>Results</h3><div>Biomarker results were available for 54 samples: Octaplas batches (n = 7), healthy controls (n = 6), ALF-standard medical treatment (n = 8), and ALF-PEX (n = 33). Proteomic analysis of 177 biomarkers revealed marked baseline differences between ALF and healthy controls, with ALF patients exhibiting lower levels of proteins secreted by the liver and higher levels of inflammatory cytokines and growth factors. Longitudinal analysis showed several distinct patterns with PEX. Proteins including carboxylesterase-1, hepatocyte growth factor, fetuin B, IL-6 and IL-10 showed differential expression patterns longitudinally, indicating some of the potential underlying mechanisms and therapeutic effects of PEX.</div></div><div><h3>Conclusions</h3><div>PEX in ALF patients leads to dynamic proteomic changes, reflecting its multifaceted role in modulating inflammation, liver regeneration and replacing essential proteins. These findings provide insight into some of the changes in circulating blood proteins and underlying mechanisms of PEX.</div></div>","PeriodicalId":49422,"journal":{"name":"Transfusion and Apheresis Science","volume":"64 1","pages":"Article 104028"},"PeriodicalIF":1.4,"publicationDate":"2024-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142683226","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}